22.05.2013 - Danish Novo A/S has strengthened its pipeline of anti-infectives against multidrug resistant bugs by acquiring Norwegian Xellia Pharmaceuticals.
The holding company of the Danish insulin producer Novo Nordisk purchased all shares of Xellia from 3i and other shareholders. As a consequence of the US$700m transaction, Xellia’s headquarters will move from Oslo to Copenhagen. The API manufacturer, which was spun-out from Alpharma Inc in 2008, is the leading supplier of the last resort antibiotic Vancomycin, the Gram-negative killing drug Colistimethate Sodium (CMS), antifungal medicines and corticosteroids.
Xellia has built a pipeline of generic anti-infective treatments, and has extensive semi-synthetic and biological manufacturing know-how, including strain development and manufacturing. Novo's investment will allow Xellia to boost its R&D and to improve its market reach.
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more